Syndax Pharmaceuticals SNDX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's EPS (diluted)?
- Syndax Pharmaceuticals (SNDX) reported EPS (diluted) of -$0.48 in Q1 2026.
- How has Syndax Pharmaceuticals's EPS (diluted) changed year-over-year?
- Syndax Pharmaceuticals's EPS (diluted) increased by 51.0% year-over-year, from -$0.98 to -$0.48.
- What is the long-term trend for Syndax Pharmaceuticals's EPS (diluted)?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's EPS (diluted) has grown at a 63.5% compound annual growth rate (CAGR), from $0.46 to -$3.29.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.